Efficacy and safety of islet autotransplantation after total pancreatectomy in chronic pancreatitis: A systematic review and meta-analysis including 17 studies - 03/09/20
, Dan-Dan Duan b, Hang Yuan cBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 11 |
| Iconografia | 7 |
| Video | 0 |
| Altro | 0 |
Highlights |
• | What is already known on this subject? Islet autotransplantation (IAT), in conjunction with total pancreatectomy (TP), is used to relieve pain in patients with chronic pancreatitis, while reducing the incidence of brittle diabetes. However, the efficacy and safety of islet autotransplantation after total pancreatectomy (TPIAT) are still unclear. |
• | What are the new findings? TPIAT can effectively relieve pain and reduce the risk of surgical diabetes with no increase in mortality or morbidity. Even if patients cannot achieve insulin independence, they can significantly improve the quality of life. |
• | How might it impact on clinical practice in the foreseeable future? Chronic pancreatitis who underwent total pancreatectomy should be treated with islet autotransplantation to prevent surgical diabetes. |
Summary |
Aims |
Islet autotransplantation (IAT), in conjunction with total pancreatectomy (TP), is used to relieve pain in patients with chronic pancreatitis (CP), while reducing the incidence of brittle diabetes. We aimed to evaluate the efficacy and safety of IAT after TP (TPIAT) in this setting.
Methods |
We searched PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials since 1977. Data were extracted from published papers. Random-effects meta-analysis and meta-regression models were built to assess the outcomes and effect of different factors. Subgroup and sensitivity analyses were conducted to examine the between-study heterogeneity, which was assessed using Cochrane's Q and I2 statistic.
Results |
A total of 17 studies, including 1024 patients, met the eligibility criteria. The median cohort size was 21 patients (range: 5–409). The pooled incidence rates of insulin independence, narcotic independence and mortality at last follow-up were 11.47 per 100 patient-years (95% CI: 6.79–21.60, I2=91.0%), 18.11 per 100 patient-years (95% CI: 5.29–62.04, I2=98.8%) and 2.88 per 100 patient-years (95% CI: 1.75–4.74, I2=46.8%), respectively. However, the heterogeneity level of our results was high, which was due to differences in research methods and definitions of outcomes between studies. Therefore, our results should be interpreted with caution.
Conclusions |
TPIAT can effectively relieve pain and reduce the risk of surgical diabetes with no increase in mortality or morbidity. Prospective, randomized, clinical trials are required to further evaluate selection of patients and the timing of TPIAT.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Islet, Autotransplantation, Pancreatectomy, Pancreatitis
Abbreviations : TP, IAT, TPIAT, CP, NOS, 95% Cis, HbA1c, NI, II, IEQ, DM, NR, PY
Mappa
Vol 44 - N° 4
P. 598-608 - Settembre 2020 Ritorno al numero
Articolo precedente
- Gammadelta T cells as a predictor of surgical relapse of Crohn's disease
- J.C. Andreu-Ballester, I. Catalán-Serra, R. Gil-Borrás, P. Marqués-García, C. García-Ballesteros, F. López Chuliá, C. Cuéllar
- Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study
- Nicolas Petitdidier, Laurent Beaugerie, Franck Carbonnel, Anne Bourrier, Xavier Treton, Sylvie Rajca, Georgia Malamut, Vered Abitbol, Matthieu Allez, Anne-Laure Pelletier, Lysiane Marthey, Pauline Jouet, Robert Benamouzig, Xavier Amiot, Yoram Bouhnik, Aurelien Amiot
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?